GATA25 Antibody

Antibody Overview

GATA antibodies target transcription factors containing zinc finger domains that regulate cellular differentiation. While no "GATA25" antibody exists, these are key antibodies for related targets:

Key Antibodies

GATA-2 Antibody Findings

• Hematopoietic Regulation: Pathogenic GATA2 variants (e.g., T354M, R307W) retain enhancer activation capacity but disrupt myeloid/erythroid differentiation balance, elevating C/EBPε levels in leukemogenesis .

• Cellular Localization: Nuclear staining confirmed in HepG2 hepatoma cells (50 kDa band) and SH-SY5Y neuroblastoma cells using AF2046 at 5 µg/mL .

• Technical Performance:

  • Western blot detection: 51-58 kDa bands in K562 leukemia cells (MAB2046) vs. 64 kDa in KG-1 cells (AF2046) .

  • Simple Western validation: 66 kDa apparent MW in HEL cells (NBP1-82581) .

GATA-5 Antibody Findings

• DNA Interaction: Chromatin immunoprecipitation (ChIP) demonstrated binding to mucin4 promoter regions in HeLa cells using AF2170 .

• Tissue Specificity: Nuclear localization observed in HepG2 cells at 1.7 µg/mL .

Comparative Data Table

Technical Considerations

• Buffer Compatibility: All antibodies tested with Immunoblot Buffer Group 1 (Tris-glycine) .

• Cross-Reactivity:

  • AF2046 detects both human and mouse GATA-2

  • #72445 shows human-specific reactivity

• Storage: Stable for 12 months at -70°C; reconstituted aliquots last 6 months .

Research Implications

• GATA-2 antibodies enable studies of enhancer-dependent transcriptional mechanisms in myelodysplastic syndromes .

• Discrepancies in observed molecular weights (51-66 kDa) suggest post-translational modifications or isoform-specific detection .